Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model

I. Kenessey, Zsófia Kramer, Lilla István, Mihály T. Cserepes, Tamás Garay, B. Hegedűs, J. Dobos, J. Tímár, J. Tóvári

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Oncogenic activation of the epidermal growth factor receptor (EGFR) signaling pathway occurs in a variety of tumor types, albeit in human melanoma, the contribution of EGFR is still unclear. The potential role of EGFR was analyzed in four BRAF-mutant, one NRAS-mutant and one wild-type NRAS-BRAF-carrying human melanoma cell lines. We have tested clinically available reversible tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, irreversible EGFR-TKI pelitinib and a reversible experimental compound PD153035 on in-vitro proliferation, apoptosis, migration as well as in-vivo metastatic colonization in a spleen-liver model. The presence of the intracellular domain of EGFR protein and its constitutive activity were demonstrated in all cell lines. Efficacies of EGFR-TKIs showed significant differences, and irreversible inhibition had the strongest antitumor potential. Compared with BRAF-mutant cells, wild-type BRAF was associated with relative resistance against gefitinib. In combination with gefitinib, selective mutant BRAF-inhibitor vemurafenib showed additive effect in all BRAF-mutant cell lines. Treatment of BRAF-mutant cells with gefitinib or pelitinib attenuated in-vitro cell migration and in-vivo colonization. Our preclinical data suggest that EGFR is a potential target in the therapy of BRAF-mutant malignant melanoma; however, more benefits could be expected from irreversible EGFR-TKIs and combined treatment settings.

Original languageEnglish
Pages (from-to)536-546
Number of pages11
JournalMelanoma Research
Volume28
Issue number6
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Epidermal Growth Factor Receptor
Melanoma
Protein-Tyrosine Kinases
Cell Line
PLX4032
Cell Movement
Spleen
Apoptosis
gefitinib
Liver
Neoplasms
Proteins

Keywords

  • epidermal growth factor receptor
  • human malignant melanoma
  • metastasis
  • small molecule tyrosine kinase inhibitors
  • xenograft

ASJC Scopus subject areas

  • Oncology
  • Dermatology
  • Cancer Research

Cite this

Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model. / Kenessey, I.; Kramer, Zsófia; István, Lilla; Cserepes, Mihály T.; Garay, Tamás; Hegedűs, B.; Dobos, J.; Tímár, J.; Tóvári, J.

In: Melanoma Research, Vol. 28, No. 6, 01.12.2018, p. 536-546.

Research output: Contribution to journalArticle

@article{82d307abe4f240a1883d957212357132,
title = "Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model",
abstract = "Oncogenic activation of the epidermal growth factor receptor (EGFR) signaling pathway occurs in a variety of tumor types, albeit in human melanoma, the contribution of EGFR is still unclear. The potential role of EGFR was analyzed in four BRAF-mutant, one NRAS-mutant and one wild-type NRAS-BRAF-carrying human melanoma cell lines. We have tested clinically available reversible tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, irreversible EGFR-TKI pelitinib and a reversible experimental compound PD153035 on in-vitro proliferation, apoptosis, migration as well as in-vivo metastatic colonization in a spleen-liver model. The presence of the intracellular domain of EGFR protein and its constitutive activity were demonstrated in all cell lines. Efficacies of EGFR-TKIs showed significant differences, and irreversible inhibition had the strongest antitumor potential. Compared with BRAF-mutant cells, wild-type BRAF was associated with relative resistance against gefitinib. In combination with gefitinib, selective mutant BRAF-inhibitor vemurafenib showed additive effect in all BRAF-mutant cell lines. Treatment of BRAF-mutant cells with gefitinib or pelitinib attenuated in-vitro cell migration and in-vivo colonization. Our preclinical data suggest that EGFR is a potential target in the therapy of BRAF-mutant malignant melanoma; however, more benefits could be expected from irreversible EGFR-TKIs and combined treatment settings.",
keywords = "epidermal growth factor receptor, human malignant melanoma, metastasis, small molecule tyrosine kinase inhibitors, xenograft",
author = "I. Kenessey and Zs{\'o}fia Kramer and Lilla Istv{\'a}n and Cserepes, {Mih{\'a}ly T.} and Tam{\'a}s Garay and B. Hegedűs and J. Dobos and J. T{\'i}m{\'a}r and J. T{\'o}v{\'a}ri",
year = "2018",
month = "12",
day = "1",
doi = "10.1097/CMR.0000000000000488",
language = "English",
volume = "28",
pages = "536--546",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model

AU - Kenessey, I.

AU - Kramer, Zsófia

AU - István, Lilla

AU - Cserepes, Mihály T.

AU - Garay, Tamás

AU - Hegedűs, B.

AU - Dobos, J.

AU - Tímár, J.

AU - Tóvári, J.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Oncogenic activation of the epidermal growth factor receptor (EGFR) signaling pathway occurs in a variety of tumor types, albeit in human melanoma, the contribution of EGFR is still unclear. The potential role of EGFR was analyzed in four BRAF-mutant, one NRAS-mutant and one wild-type NRAS-BRAF-carrying human melanoma cell lines. We have tested clinically available reversible tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, irreversible EGFR-TKI pelitinib and a reversible experimental compound PD153035 on in-vitro proliferation, apoptosis, migration as well as in-vivo metastatic colonization in a spleen-liver model. The presence of the intracellular domain of EGFR protein and its constitutive activity were demonstrated in all cell lines. Efficacies of EGFR-TKIs showed significant differences, and irreversible inhibition had the strongest antitumor potential. Compared with BRAF-mutant cells, wild-type BRAF was associated with relative resistance against gefitinib. In combination with gefitinib, selective mutant BRAF-inhibitor vemurafenib showed additive effect in all BRAF-mutant cell lines. Treatment of BRAF-mutant cells with gefitinib or pelitinib attenuated in-vitro cell migration and in-vivo colonization. Our preclinical data suggest that EGFR is a potential target in the therapy of BRAF-mutant malignant melanoma; however, more benefits could be expected from irreversible EGFR-TKIs and combined treatment settings.

AB - Oncogenic activation of the epidermal growth factor receptor (EGFR) signaling pathway occurs in a variety of tumor types, albeit in human melanoma, the contribution of EGFR is still unclear. The potential role of EGFR was analyzed in four BRAF-mutant, one NRAS-mutant and one wild-type NRAS-BRAF-carrying human melanoma cell lines. We have tested clinically available reversible tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, irreversible EGFR-TKI pelitinib and a reversible experimental compound PD153035 on in-vitro proliferation, apoptosis, migration as well as in-vivo metastatic colonization in a spleen-liver model. The presence of the intracellular domain of EGFR protein and its constitutive activity were demonstrated in all cell lines. Efficacies of EGFR-TKIs showed significant differences, and irreversible inhibition had the strongest antitumor potential. Compared with BRAF-mutant cells, wild-type BRAF was associated with relative resistance against gefitinib. In combination with gefitinib, selective mutant BRAF-inhibitor vemurafenib showed additive effect in all BRAF-mutant cell lines. Treatment of BRAF-mutant cells with gefitinib or pelitinib attenuated in-vitro cell migration and in-vivo colonization. Our preclinical data suggest that EGFR is a potential target in the therapy of BRAF-mutant malignant melanoma; however, more benefits could be expected from irreversible EGFR-TKIs and combined treatment settings.

KW - epidermal growth factor receptor

KW - human malignant melanoma

KW - metastasis

KW - small molecule tyrosine kinase inhibitors

KW - xenograft

UR - http://www.scopus.com/inward/record.url?scp=85055614515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055614515&partnerID=8YFLogxK

U2 - 10.1097/CMR.0000000000000488

DO - 10.1097/CMR.0000000000000488

M3 - Article

C2 - 30124539

AN - SCOPUS:85055614515

VL - 28

SP - 536

EP - 546

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 6

ER -